Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4CNS 4Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Colonic Neoplasms 11Pancreatic Neoplasms 10Rectal Neoplasms 7Stomach Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Renal Cell 5Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Hepatocellular 4Astrocytoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Liver Neoplasms 2Gallbladder Neoplasms 2Familial ependymoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

Magnetic Resonance Spectroscopy 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2LY3023414 2sargramostim 1pembrolizumab 1entinostat 1dostarlimab 1cediranib 1Thiotepa 1Thalidomide 1Tamoxifen 1Sirolimus 1Radiotherapy, Image-Guided 1Radiotherapy 1Pharmacogenomic Variants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × sargramostim × Gastrointestinal × Clear all
NCT00069940 2010-12-28

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
CNSGastrointestinalSarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Leiomyosarcoma, Liposarcoma, Oligodendroglioma, Sarcoma, Sarcoma, Synovial, Central Nervous System Neoplasms, Gliosarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡